Is concern about cardiovascular events with the new coxib class of drugs justified?
Schnitzer
T J
TJ
D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D003627:Data Interpretation, Statistical; D004341:Drug Evaluation; D006801:Humans; D007783:Lactones / Q000008:administration & dosage / Q000009:adverse effects*; D009203:Myocardial Infarction / Q000139:chemically induced*; D011720:Pyrazoles; D020521:Stroke / Q000139:chemically induced*; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*; D013450:Sulfones
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000068579:Celecoxib